GlassScriptPhysician profile
Ryan Joseph Wolfe
NPI 1568090173
$3,038.13
in general payments reported to CMS, 2019-2025
20 companies · $2,082 in 2025
The $2,082 reported for 2025 was more than what 96% of General Practice providers received nationally (typical 2025 total: $105).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $15.98 · 2023: $292 · 2024: $648 · 2025: $2,082.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,296 · Travel and Lodging: $726.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,295.80 |
| Travel and Lodging | $726.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $1,571.56 | 2023-2025 | General - Therapies, Wavewriter Alpha Prime 16 |
| Medtronic, INC. | $393.15 | 2023-2025 | Intellis Adaptivestim, Unid_pass, Kyphon Express II Kyphopak Tray |
| Nalu Medical, INC. | $151.71 | 2024 | Nalu Neurostimulation System |
| Ipsen Biopharmaceuticals, INC | $147.45 | 2023-2025 | Dysport |
| Globus Medical, INC. | $136.58 | 2025 | Senza |
| Averitas Pharma INC. | $122.10 | 2024 | Qutenza |
| Si-Bone, INC. | $98.21 | 2025 | |
| Avanos Medical | $68.17 | 2024 | Coolief* Cooled Radiofrequency |
| Abbvie INC. | $63.93 | 2023-2025 | Botox |
| Spr Therapeutics, INC | $49.13 | 2023 | Sprint Pns System |
| Collegium Pharmaceutical, INC. | $45.53 | 2025 | Belbuca |
| Merz Pharmaceuticals, LLC | $38.36 | 2023 | Xeomin |
| Lundbeck LLC | $29.45 | 2024 | Vyepti |
| Biotronik Nro, INC. | $27.10 | 2025 | Prospera |
| Azurity Pharmaceuticals, INC. | $18.51 | 2023 | Horizant |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka Pharmaceutical Development & Commercialization, INC. | $18.26 | 2025 | Rexulti |
| Vertex Pharmaceuticals Incorporated | $16.13 | 2025 | |
| Biohaven Pharmaceutical Holding Company LTD. | $15.98 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $13.63 | 2025 | Relistor |
| Pfizer INC. | $13.19 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ryan Wolfe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.